Biogen: Earnings Beat Expectations, Maintaining Current Fair Value Estimate

Despite CEO uncertainty, we remain confident in the firm's wide moat and competitive advantages in neurology.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.